ASTRAZENECA
A CULTURE OF INCLUSION AND DIVERSITY PUSHING THE BOUNDARIES OF SCIENCE TO DELIVER LIFE-CHANGING MEDICINES AstraZeneca is one of the world’s most exciting bio-pharmaceutical companies. Operating in over 100 countries, we focus on the discovery, development and commercialisation of prescription medicines. We, however, are not your typical bio-pharmaceutical company - here pioneers, ‘ubuntu warriors’, future leaders, convention challengers and game changers, collaborate side by side to turn ideas into life-changing medicines and healthcare initiatives that improve patients’ lives and benefit society. AstraZeneca Pharmaceuticals is a company that anchors diversity in our values and embeds it in business to improve our ability to connect and respond in a changing world. Proof that this is not just sentiment, is that of the nearly 165 team members employed locally, an incredible 69% are women, of which 39% are in middle management or higher.
AstraZeneca has been working with healthcare stakeholders in Africa for over 27 years to ensure that more patients in Africa have access to high quality healthcare, such as prevention and screening programmes to support early intervention, treatment and disease management. We focus on innovative science and leadership in our four main therapy areas: areas: oncology; renal and metabolism; cardiovascular; and respiratory and immunology. COMMITMENT TO SUSTAINABLE HEALTHCARE AND TO OUR COMMUNITIES The AstraZeneca C-suite includes nine innovative female leaders (69%), led by Barbara Nel, Country President for South Africa, Sub Saharan and French Speaking Africa, who are positively impacting and shaping the healthcare industry. Their shared passion and drive has seen the introduction and expansion of a number of innovative Health Access
44 S TANDARD BANK TO P W O M EN LEADERS
Programmes over the past 12 months that span non-communicable diseases. Amongst these are: • Africa PUMUA Initiative (breathe) which aims to redefine asthma care in Africa for paediatric and asthma patients in the private and public sectors through partnership with governments, healthcare professionals and societies. • AstraZeneca’s non communicable disease (NCD) screening partnership, with the Ministry of Health in South Africa, supports the vision of task-shifting to ensure earlier access to screening and diagnosis of patients, with a focus on high blood pressure screening. • The introduction of the Kamba Ya Shanga Pharmacy initiative in South Africa, in partnership with the Independent Community Pharmacists Association (ICPA), offers a pharmacist-led disease management and referral programme. • The extension of AstraZeneca’s Phakamisa programme, providing access to care initiatives currently focused on improving breast and prostate cancer management, specifically addresses early detection of disease, promotion
